Robuta

https://www.sitryx.com/news/sitryx-presents-new-preclinical-data-highlighting-pkm2-as-a-promising-metabolic-target-for-the-treatment-of-atopic-dermatitis-at-the-inflammatory-disease-skin-summit-2025 Sitryx presents new preclinical data highlighting PKM2 as a promising metabolic target for the... presents newpreclinical datasitryxhighlightingpromising https://www.sitryx.com/news/sitryx-therapeutics-strengthens-leadership-team-with-appointment-of-ravi-m-rao-as-chief-medical-officer Sitryx Therapeutics strengthens leadership team with appointment of Ravi M. Rao as Chief Medical... therapeutics strengthensleadership teamsitryxappointmentravi https://www.sitryx.com/news/sitryx-ceo-neil-weir-presents-at-lsx-world-congress-2023 Sitryx CEO, Neil Weir, presents at LSX World Congress 2023 - Sitryx world congresssitryxceoneilweir https://www.sitryx.com/news/sitryx-to-attend-j-p-morgan-healthcare-conference-2026-showcasing-pipeline-of-novel-small-molecule-candidates-targeting-major-autoimmune-indications Sitryx to attend J.P. Morgan Healthcare Conference 2026 showcasing pipeline of novel small molecule... morgan healthcaresitryxattendconferenceshowcasing https://www.sitryx.com/news/sitryx-ceo-neil-weir-presents-at-bioequity-europe-2023-on-respiratory-and-dermatological-disease Sitryx CEO, Neil Weir, presents at BioEquity Europe 2023 - Sitryx sitryxceoneilweirpresents https://www.sitryx.com/news/boehringer-ingelheim-licenses-novel-oral-therapeutics-program-for-immune-diseases-from-sitryx-therapeutics Boehringer Ingelheim licenses novel oral therapeutics program for immune diseases from Sitryx... boehringer ingelheimlicensesnoveloraltherapeutics https://www.sitryx.com/news/sitryx-raises-additional-39-million-to-progress-development-of-disease-modifying-therapeutics-for-chronic-autoimmune-and-inflammatory-diseases Sitryx raises additional $39 million to progress development of disease-modifying therapeutics for... disease modifyingsitryxraisesadditionalmillion https://www.sitryx.com/news/2025-our-year-in-review 2025: Our Year in Review - Sitryx yearreviewsitryx https://www.sitryx.com/news/sitryx-regains-rights-to-syx-1042-itaconate-mimetic-for-chronic-autoimmune-and-inflammatory-diseases-from-lilly-following-portfolio-reprioritization Sitryx regains rights to SYX-1042 itaconate mimetic for chronic autoimmune and inflammatory... sitryxregainsrightssyxmimetic https://www.sitryx.com/news/sitryx-appoints-pierre-legault-as-chairman-of-its-board-of-directors Sitryx appoints Pierre Legault as Chairman of its Board of Directors - Sitryx sitryxappointspierrelegaultchairman https://www.sitryx.com/news/sitryx-therapeutics-announces-participation-at-the-longwood-healthcare-leaders-pre-jpm-webconference-january-5th-january-6th-2023 Sitryx Therapeutics Announces Participation at the Longwood Healthcare Leaders Pre-JPM... therapeutics announceshealthcare leaderssitryxparticipationlongwood https://www.sitryx.com/privacy-policy Privacy Policy - Sitryx privacy policysitryx https://www.sitryx.com/licensing Licensing & Partnering - Sitryx Sitryx Therapeutics has a team of energetic and dedicated scientists, building a broad pipeline of novel agents targeting immunometabolic pathways to resolve... licensingpartneringsitryx https://www.sitryx.com/investors Investors - Sitryx investorssitryx https://www.sitryx.com/careers Careers - Sitryx careerssitryx https://www.sitryx.com/news/sitryx-therapeutics-to-participate-in-wells-fargo-virtual-private-biotech-symposium Sitryx Therapeutics to Participate in Wells Fargo Virtual Private Biotech Symposium - Sitryx wells fargovirtual privatesitryxtherapeuticsparticipate https://www.sitryx.com/news/sitryx-announces-partner-lilly-exercises-option-to-sit-011-for-chronic-autoimmune-and-inflammatory-diseases Sitryx announces partner Lilly exercises option to SIT-011 for chronic autoimmune and inflammatory... sitryxannouncespartnerlillyexercises https://www.sitryx.com/news/sitryx-announces-leadership-transition Sitryx announces leadership transition - Sitryx announces leadershipsitryxtransition https://www.sitryx.com/news/sitryx-therapeutics-announces-presentation-at-the-stifel-2022-healthcare-conference Sitryx Therapeutics announces presentation at the Stifel 2022 Healthcare Conference - Sitryx therapeutics announcessitryxpresentationstifelhealthcare https://www.sitryx.com/news News - Sitryx newssitryx https://www.sitryx.com/news/sitryx-nominates-sit-047-a-novel-oral-mthfd2-inhibitor-for-clinical-development-in-psoriatic-arthritis Sitryx nominates SIT-047, a novel, oral MTHFD2 inhibitor, for clinical development in psoriatic... clinical developmentsitryxnominatesnoveloral https://www.sitryx.com/contact Contact - Sitryx sitryx https://www.sitryx.com/news/sitryx-to-participate-in-upcoming-investor-conferences Sitryx receives FDA clearance of IND application for SYX-5219 for the treatment of atopic... receives fda clearancesitryxindapplicationsyx https://www.sitryx.com/news/sitryx-nominates-novel-oral-gls1-inhibitor-for-clinical-development-in-moderate-to-severe-asthma Sitryx nominates novel, oral GLS1 inhibitor for clinical development in moderate to severe asthma -... clinical developmentsitryxnominatesnoveloral https://www.sitryx.com/news/sitryx-advances-development-of-pkm2-modulator-syx-5219-into-atopic-dermatitis-patients-following-clinical-evidence-of-immunomodulatory-activity Sitryx advances development of PKM2 modulator SYX-5219 into atopic dermatitis patients following... atopic dermatitissitryxadvancesdevelopmentmodulator https://www.sitryx.com/news/sitryx-appoints-adam-mostafa-as-chief-financial-officer Sitryx appoints Adam Mostafa as Chief Financial Officer - Sitryx chief financialsitryxappointsadammostafa https://www.sitryx.com/news/immunometabolism-company-sitryx-expands-into-new-space-at-tosp-second-occupier-for-bellhouse-building-at-the-oxford-science-park-oxford-uk Immunometabolism company Sitryx expands into new space at TOSP Second occupier for Bellhouse... new spacecompanysitryxexpandssecond https://www.sitryx.com/news/sitryx-to-participate-in-upcoming-healthcare-investor-conferences Sitryx to participate in upcoming healthcare investor conferences - Sitryx sitryxparticipateupcominghealthcareinvestor https://www.sitryx.com/events Events - Sitryx eventssitryx https://www.sitryx.com/news/sitryx-therapeutics-announces-participation-in-upcoming-conferences Sitryx Therapeutics Announces Presentation at the 2022 Bio International Convention - Sitryx therapeutics announcesbio internationalsitryxpresentationconvention https://www.sitryx.com/news/sitryx-appoints-lisa-pierre Sitryx stren - Sitryx sitryx https://www.sitryx.com/news/sitryx-presents-new-preclinical-data-highlighting-mthfd2-as-a-novel-metabolic-target-in-autoimmune-disease-at-acr-convergence-2025 Sitryx presents new preclinical data highlighting MTHFD2 as a novel metabolic target in autoimmune... presents newpreclinical datasitryxhighlightingnovel https://www.sitryx.com/pipeline Pipeline - Sitryx pipelinesitryx https://www.sitryx.com/about About - Sitryx sitryx https://www.sitryx.com/ Pioneers in immunometabolism - Sitryx We’re altering immune cell metabolism to resolve disease. The field of immunometabolism is a rapidly emerging and exciting area of investigation into the role... pioneerssitryx